MYAM
MRNA icon

Meiji Yasuda Asset Management’s Moderna MRNA Stock Holding History

Meiji Yasuda Asset Management’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-5,064
Closed -$338K – 689
2024
Q3 		$338K Buy
5,064
+177
+4% +$16.3K 0.01% 523
2024
Q2 		$580K Buy
4,887
+287
+6% +$36.3K 0.02% 399
2024
Q1 		$490K Buy
4,600
+850
+23% +$85.7K 0.02% 436
2023
Q4 		$373K Buy
3,750
+140
+4% +$11.8K 0.02% 437
2023
Q3 		$373K Buy
3,610
+393
+12% +$43.8K 0.02% 482
2023
Q2 		$391K Sell
3,217
-138
-4% -$18.4K 0.02% 456
2023
Q1 		$515K Sell
3,355
-130
-4% -$21.4K 0.03% 396
2022
Q4 		$626 Sell
3,485
-210
-6% -$34.3K 0.03% 390
2022
Q3 		$437K Sell
3,695
-520
-12% -$78.9K 0.03% 439
2022
Q2 		$602K Buy
4,215
+310
+8% +$44.3K 0.03% 410
2022
Q1 		$673K Sell
3,905
-293
-7% -$49.3K 0.04% 397
2021
Q4 		$1.07M Sell
4,198
-5,349
-56% -$1.56M 0.07% 264
2021
Q3 		$3.67M Buy
9,547
+497
+5% +$183K 0.26% 101
2021
Q2 		$2.13M Buy
9,050
+6,230
+221% +$1.11M 0.1% 162
2021
Q1 		$369K Buy
+2,820
New +$409K 0.03% 399
2020
Q3 		– Sell
-3,600
Closed -$231K – 418
2020
Q2 		$231K Buy
+3,600
New +$197K 0.02% 431

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Meiji Yasuda Asset Management's MRNA Position: Q4 2024 in Review

Meiji Yasuda Asset Management sold out of Moderna (MRNA) in Q4 2024, closing a stake of 5,064 shares — an estimated $338K sold.

Meiji Yasuda Asset Management first reported a position in MRNA in Q2 2020 and held it in 16 quarters. The position peaked at $3.67M in Q3 2021. 745 funds tracked by Wall St. Rank hold MRNA as of Q4 2024.

  • Meiji Yasuda Asset Management reported no remaining Moderna position as of Q4 2024 after selling out during the quarter.
  • Meiji Yasuda Asset Management sold 5,064 Moderna shares in Q4 2024, an estimated $338K.
  • Meiji Yasuda Asset Management first reported a position in Moderna in Q2 2020 and held it in 16 quarters.
  • Meiji Yasuda Asset Management's Moderna position peaked at $3.67M in Q3 2021.
  • 745 funds tracked by Wall St. Rank held Moderna as of Q4 2024.

Based on Meiji Yasuda Asset Management's 13F filing for Q4 2024, filed 12 Feb 2025.